Literature DB >> 29864910

Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2.

Yu Wang1, Shulan Zhang2.   

Abstract

Berberin (BBR), an alkaloid mainly found in Huang Lian (Rhizoma coptidis) and other medicinal herbs, has been reported to exhibit anti-tumor activities against several types of tumor. The biological function of BBR in endometrial cancer (EC) and the underlying molecular mechanisms, however, remain unknown. In this study, BBR was found to inhibit growth, migration, invasion and metastasis of EC cells, both in vitro and in vivo. BBR was also able to suppress tumor through cyclooxygenase-2 (COX-2)/ prostaglandin E2 (PGE2) signaling pathways. Transcription of miR-101 was upregulated by BBR via activator protein 1 (AP-1) in order to modulate the transcription of COX-2 in EC cells. In summary, BBR inhibited EC tumor growth and metastasis via miR-101/COX-2/PGE2 signaling pathways, suggesting the usage of BBR as a potential anticancer drug for treating EC.
Copyright © 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Berberin; Cyclooxygenase-2; Endometrial cancer; miR-101

Mesh:

Substances:

Year:  2018        PMID: 29864910     DOI: 10.1016/j.biopha.2018.04.161

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  22 in total

1.  Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1.

Authors:  Jian Pu; Xianjian Wu; Yi Wu; Zesheng Shao; Chunying Luo; Qianli Tang; Jianchu Wang; Huamei Wei; Yuan Lu
Journal:  Aging (Albany NY)       Date:  2021-03-22       Impact factor: 5.682

2.  Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation.

Authors:  Guanyu Li; Tong Wang; Xiaoyi Zhang; Shurui Zhao; Yaonan Wang; Jianhui Wu; Shiqi Peng; Ming Zhao
Journal:  Drug Des Devel Ther       Date:  2020-06-03       Impact factor: 4.162

Review 3.  Overcoming cancer therapeutic bottleneck by drug repurposing.

Authors:  Zhe Zhang; Li Zhou; Na Xie; Edouard C Nice; Tao Zhang; Yongping Cui; Canhua Huang
Journal:  Signal Transduct Target Ther       Date:  2020-07-02

Review 4.  The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches.

Authors:  Solomon Habtemariam
Journal:  Biomedicines       Date:  2020-04-18

5.  Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake.

Authors:  Pengcheng Zhang; Quancheng Wang; Zhibin Lin; Peijun Yang; Kefeng Dou; Ruohan Zhang
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

6.  Identifying Synergistic Mechanisms of Multiple Ingredients in Shuangbai Tablets against Proteinuria by Virtual Screening and a Network Pharmacology Approach.

Authors:  Xiaoqin Ma; Meixiang Yu; Chenxia Hao; Wanhua Yang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-06       Impact factor: 2.629

Review 7.  Antitumor effects and molecular mechanisms of action of natural products in ovarian cancer.

Authors:  Yun-Bo Yan; Qing Tian; Ji-Fang Zhang; Ying Xiang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

8.  Berberine promotes XIAP-mediated cells apoptosis by upregulation of miR-24-3p in acute lymphoblastic leukemia.

Authors:  Jian Liu; Zhiwei Chen; Yunping Cui; Huixia Wei; Zhenjing Zhu; Fengxia Mao; Yingchao Wang; Yufeng Liu
Journal:  Aging (Albany NY)       Date:  2020-02-13       Impact factor: 5.682

Review 9.  Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization.

Authors:  Solomon Habtemariam
Journal:  Molecules       Date:  2020-03-20       Impact factor: 4.411

10.  13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein.

Authors:  Guanyu Li; Yi Ren; Xiaoyi Zhang; Shurui Zhao; Yaonan Wang; Jianhui Wu; Shiqi Peng; Ming Zhao
Journal:  Onco Targets Ther       Date:  2019-12-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.